Related Experiment Video

Updated: Jul 13, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Antiretroviral HIV treatment and care for injecting drug users: an evidence-based overview

France Lert1, Michel D Kazatchkine

  • 1INSERM U687, Saint-Maurice, France.

The International Journal on Drug Policy
|August 11, 2007
PubMed

Insights

Highly active antiretroviral treatment (HAART) has improved HIV outcomes, but benefits are less pronounced for injecting drug users (IDUs). Comprehensive care addressing both HIV and drug dependence is crucial for this population.

Area of Science:

  • Public Health
  • Infectious Diseases
  • Addiction Medicine

Background:

  • Highly active antiretroviral treatment (HAART) has significantly reduced AIDS mortality and progression.
  • HIV-infected injecting drug users (IDUs) experience poorer outcomes compared to other patient groups.
  • Factors contributing to poorer outcomes include co-infections, delayed treatment, lower adherence, and ongoing substance use.

Purpose of the Study:

  • To highlight the disparities in HAART effectiveness among HIV-infected IDUs.
  • To identify key factors contributing to suboptimal outcomes in this population.
  • To advocate for integrated care strategies for HIV-infected IDUs.

Main Methods:

  • Review of existing evidence on HIV treatment outcomes in IDUs.
  • Analysis of factors associated with poorer health outcomes in HIV-infected IDUs.
  • Synthesis of data to support comprehensive care models.

Main Results:

  • HIV-infected IDUs show lesser overall benefit from HAART compared to other populations.
  • Non-HIV-related deaths, hepatitis C co-infection, and delayed treatment access are prevalent.
  • Lower adherence, continued illicit drug use, and mental health issues negatively impact outcomes.

Conclusions:

  • Comprehensive treatment and care strategies are essential for HIV-infected IDUs.
  • Integration of drug dependence treatment with HAART is strongly recommended.
  • Addressing multifaceted challenges is key to improving health outcomes for IDUs with HIV.

More Related Videos

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Sexually Transmitted Infections01:26

Sexually Transmitted Infections

Sexually transmitted infections (STIs) are diseases transmitted primarily through unsafe sexual interactions. Bacteria, viruses, or parasites cause them and can result in severe health complications if untreated.ChlamydiaThe bacterium Chlamydia trachomatis is responsible for the disease Chlamydia, the most common STI in the United States. This peculiar pathogen requires human cells to reproduce, residing intracellularly. The initial infection often goes unnoticed because it typically does not...
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.